Drug Department asking for documents to be notarizerd. What does it means? How documents should be notarized?
Notary means a person authorized to perform certain legal formalities, especially to draw up or certify contracts, deeds, and other documents for... Read More
Why user documents asked while submitting trademark for registration?
Posted on01 Apr 2019
Comments0
Suppose you want to file a pharmaceutical trademark, department may ask for the user documents. User documents are proof that shows you... Read More
Check Your Competency in Data Integrity
Data Integrity refers to maintaining and assuring the accuracy and consistency of data over its entire product life-cycle. Over the last few years several, FDA... Read More
GSK’s Advair Loss of Exclusivity (LOE) and Mylan’s Wixela Inhub generic entry
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the GlaxoSmithKline’s respiratory blockbuster, Advair. ... Read More
Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals
Posted on07 Feb 2019
TagsAegerion, HoFH, Juxtapid, Novelion Therapeutics, orphan drug, orphan drug designation, rare disease
Comments0
Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
AMAG Pharmaceuticals to Acquire Perosphere and Its Anticoagulant
Posted on17 Dec 2018
Comments0
AMAG Pharmaceuticals, Inc. will acquire Perosphere Inc. to leverage its expertise in hematology. The deal will provide the company the rights to... Read More
Case Study: Insight on DRL-Indivior Suboxone Patent Battle
June 2018 : DRL got the generic approval for Suboxone Dr Reddy’ s Laboratories received approval from the USFDA for generic version... Read More